NL-OMON28722CompletedNot Applicable
Quetiapine augmentation to SRIs for patients with obsessive compulsive disorder.
Prof. dr. H.G.M. WestenbergDepartment of PsychiatryUMC UtrechtHeidelberglaan 1003584 CX UtrechtThe NetherlandsPhone: +31 30 2509019E-mail: h.g.m.westenberg@azu.nl0 sites90 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 90
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. All patients meet the DSM IV criteria for obsessive-compulsive disorder;
- •2. Y-BOCS score > 16 if obsessions and compulsions;
Exclusion Criteria
- •1. Presence of any of the following DSM IV conditions:
- •a. Major depression (with a HDRS>17, [17 item]);
Investigators
Similar Trials
Completed
Phase 2
Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg StudyObsessive Compulsive DisorderNCT00318539AstraZeneca90
Active, not recruiting
Phase 1
Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot StudyDepressionEUCTR2005-003251-13-GBAstraZeneca UK Ltd40
Terminated
Phase 3
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective DisorderSchizoaffective DisordersPsychotic DisordersSchizophreniaNCT00457899AstraZeneca234
Unknown
Phase 4
Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders PatientsBipolar I DisorderNCT01710163University of Sao Paulo50
Completed
Phase 3
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)Substance Use DisordersBipolar DisorderAnxietyAnxiety DisordersNCT00671853University Hospitals Cleveland Medical Center120